

Storage: Store at room temperature

Shelf Life:3 years

Kampo product

Approval No.	16100AMZ03967000
Date of Initial Marketing in Japan	October 1986

N320

Kotaro Choyoto Extract Fine Granules

3. COMPOSITION AND PRODUCT DESCRIPTION

3.1 Composition

Brand name	Kotaro Choyoto Extract Fine Granules
Active ingredient	6.0g of Kotaro Choyoto Extract Fine Granules contains 3.7g of the dried extract of the following mixed crude drugs.
	JP Coix Seed..... 9.0g
	JP Benincasa Seed..... 6.0g
	JP Peach Kernel..... 5.0g
	JP Moutan Bark..... 4.0g (JP: Japanese Pharmacopoeia)
Excipients	Magnesium Stearate, Corn Starch, Lactose Hydrate, Pullulan, Magnesium Aluminometasilicate

3.2 Product Description

Dosage form	Fine granules
Color	Light brown
Taste	Slightly bitter
Odor	Characteristic odor
ID code	N320

4. INDICATIONS

Patients who have acute or chronic pain in the cecum or menstrual pain.

6. DOSAGE AND ADMINISTRATION

The usual adult dosage for oral use is 6.0g daily in 2 or 3 divided doses before or between meals.

The dosage may be adjusted according to the patient's age, body weight, and symptoms.

8. IMPORTANT PRECAUTIONS

8.1 When this product is used, the patient's "SHO"

(constitution/symptoms) should be taken into consideration. The patient's progress should be carefully monitored, and if no improvement in symptoms or findings is observed, continuous administration should be avoided.

8.2 When this product is used in combination with other Kampo products, etc., attention should be paid to the duplication of the contained crude drugs.

9. PRECAUTIONS CONCERNING PATIENTS WITH SPECIFIC BACKGROUNDS

9.5 Pregnant Women

It is not recommended to administer this product to pregnant women or women who may possibly be pregnant. Peach Kernel and Moutan Bark contained in this product may cause premature birth or miscarriage.

9.6 Breast-feeding Women

Considering the therapeutic benefits and the benefits of breastfeeding, continuation or discontinuation of breastfeeding should be considered.

9.7 Pediatric Use

No clinical studies have been conducted in children.

9.8 Geriatric Use

Since the physiological functions are generally decrease in elderly patients, careful supervision is recommended; measures such as reducing the dose may be considered.

11. ADVERSE REACTIONS

The following adverse reactions may occur. Patients should be carefully monitored, and if any abnormalities are observed, appropriate measures such as discontinuation of administration should be taken.

11.2 Other Adverse Reactions

	Frequency unknown
Gastrointestinal	Epigastric distress, Diarrhea, etc.

20. PRECAUTIONS FOR HANDLING

- 20.1 To maintain the quality of the product, avoid moisture as much as possible and store in a cool place, away from direct sunlight.
- 20.2 Avoid moisture, especially after opening, and handle with care.
- 20.3 Since this product is made from crude drugs, the color of the product may vary.

22. PACKAGING

- 500g[bottle,loose]
2.0g×42 packets[sachets]
2.0g×231 packets[sachets]

24. REFERENCE REQUEST AND CONTACT INFORMATION

Pharmaceutical Division, Kotaro Pharmaceutical Co., Ltd.
5-23, Nakatsu 2-chome, Kita-ku, Osaka 531-0071, Japan

26. MARKETING AUTHORIZATION HOLDER, etc.

26.1 Marketing Authorization Holder

Kotaro Pharmaceutical Co., Ltd.
5-23, Nakatsu 2-chome, Kita-ku, Osaka 531-0071, Japan